Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian V Lee

Showing results (221-230 of 236) with videos related to

Pageof 24
Sort By:
BMC Medicine|November 19, 2020
ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasisSara Charmsaz, Ben Doherty, Sinéad Cocchiglia, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Integrating Artificial Intelligence-Driven Digital Pathology and Genomics to Establish Patient-Derived Organoids as a Novel Alternative Model for Drug Response in Head and Neck CancerRose Doerfler, Jie Chen, Carl Kim, et al.
Oral Oncology|November 10, 2025
Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancerRose Doerfler, Jie Chen, Carl Kim, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older womenNeil Carleton, Sanghoon Lee, Ruxuan Li, et al.
Journal of the National Cancer Institute|July 3, 2018
Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable TargetsDamir Varešlija, Nolan Priedigkeit, Ailís Fagan, et al.
Breast Cancer Research : BCR|September 13, 2014
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Chad J Creighton, Nrusingh C Biswal, et al.
Cancer Letters|March 14, 2026
Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancerSantiago Panesso-Gómez, Alexander J Cole, Austin Arrigo, et al.
Cancer Cell|April 17, 2026
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progressionTriet Minh Bui, Ernesto Rojas Jimenez, Zheqi Li, et al.
NPJ Breast Cancer|February 20, 2026
Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programsGitte Zels, Karen Van Baelen, Alexander Cc Chang, et al.
Nature Cancer|June 27, 2025
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2<sup>+</sup> breast cancer that limits trastuzumab deruxtecan efficacyDong Hu, Xiaoshuang Lyu, Zheqi Li, et al.
Pageof 24

Showing results (221-230 of 236) with videos related to

Sort By:
Pageof 24
BMC Medicine|November 19, 2020
ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasisSara Charmsaz, Ben Doherty, Sinéad Cocchiglia, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Integrating Artificial Intelligence-Driven Digital Pathology and Genomics to Establish Patient-Derived Organoids as a Novel Alternative Model for Drug Response in Head and Neck CancerRose Doerfler, Jie Chen, Carl Kim, et al.
Oral Oncology|November 10, 2025
Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancerRose Doerfler, Jie Chen, Carl Kim, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older womenNeil Carleton, Sanghoon Lee, Ruxuan Li, et al.
Journal of the National Cancer Institute|July 3, 2018
Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable TargetsDamir Varešlija, Nolan Priedigkeit, Ailís Fagan, et al.
Breast Cancer Research : BCR|September 13, 2014
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Chad J Creighton, Nrusingh C Biswal, et al.
Cancer Letters|March 14, 2026
Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancerSantiago Panesso-Gómez, Alexander J Cole, Austin Arrigo, et al.
Cancer Cell|April 17, 2026
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progressionTriet Minh Bui, Ernesto Rojas Jimenez, Zheqi Li, et al.
NPJ Breast Cancer|February 20, 2026
Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programsGitte Zels, Karen Van Baelen, Alexander Cc Chang, et al.
Nature Cancer|June 27, 2025
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2<sup>+</sup> breast cancer that limits trastuzumab deruxtecan efficacyDong Hu, Xiaoshuang Lyu, Zheqi Li, et al.
Pageof 24